Cell viability was determined following treatment with a 10-μM TGF-β inhibitor (LY364947) and a 5-μM VEGF inhibitor (axitinib) for 24 h in cultured normal myometrium and leiomyoma cells. This evidence concerns the gene TGFB1 and leiomyoma.